Folgen

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Brett Alderson, President and Site Leader of Novacina.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Brett, covering:

    The complexities of being on the inside of big pharma looking to carve out your site... then transitioning into a customer-facing CDMOLeaning into the freedom and liberation of having the shackles off as an independent businessPairing world-class, complex commercial capabilities (100 million+ units) with a small scaler clinical offeringThe uncertainty and capacity concerns on the market after that market-shaking dealAnd just why Australia is a hub for global for clinical trials...

    Brett Alderson is a seasoned veteran in the pharmaceutical industry predominantly working with the manufacturing of sterile injectables. Brett is a determined and thoughtful leader adept at driving business success and leading through change. He is a champion for customers, instilling a customer-centric culture with transparency and helpfulness.

    He enjoys mentoring and nurturing a diverse workforce with a clear imperative of open and honest communication. Brett has a reputation as an energetic problem solver, acting with integrity and care, and always encourages solutions for a brighter tomorrow by empowering people.

    Brett’s career includes more than 25 years at Pfizer, before becoming President and Site Leader of Novacina in April 2023 where he oversaw a 500-member team and the production of more than 300 Oncology products plus several additional sterile injectable medicines for local and global markets.

    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Arvid Söderhall, CEO at Empros Pharma.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Arvid, covering:

    The personal story of a pediatrician treating an obese child that led to the creation of Empros Pharma and its lead asset The 10-year journey from an idea to a successful Phase IIb trial... and what it felt like to reach the magic milestone Critical characteristics required for a small pharma leader, and why CEOs stand and fall with their data The ins and outs of a CDMO selection process for Phase 3 trials and the commercial launch for a global drug to complement GLP-1 products How the investor climate has changed in the last 1-2 years... and how it has it turned upside down in the hot obesity space

    Arvid joined Empros as a project manager in 2013, during the company’s foundational phase, before the EMP16 project was named. He quickly ascended to CEO, steering Empros to prioritize its founders and inventors while leveraging a strong network of contacts and leading Empros to a phase 3-ready project that surpassed initial expectations.

    He holds a Ph.D. in Physical Chemistry with a specialization in Computational Chemistry. He then completed a postdoctoral fellowship in Berlin, marking his first engagement with the pharma industry and filing a first patent, introducing a foray into biotech entrepreneurship. Subsequently, Arvid worked at Stockholm-based biotech ‘Sidec,’ focusing on cryo-electron microscopy of proteins. Despite the premature technology leading to Sidec’s closure, the foundational concept later earned a Nobel Prize, underscoring the importance of timing in innovation.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

  • Fehlende Folgen?

    Hier klicken, um den Feed zu aktualisieren.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

    Sabina Ouimet-Storrs, Principal at GHO Capital PartnersJames West, Managing Director at Lincoln InternationalDerek Hennecke, investor and board member in biopharma and cell therapy manufacturing

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests, covering:

    The year of the failed process in 2023...Which sub-segments of the pharma services ecosystem are hot right now?A myriad of buys and builds, carve-outs, and platform dealsAn optimistic outlook for the year ahead... despite some significant market headwinds

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Elisabeth Stampa, President Medicines for Europe and Board Chair at Medichem.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Elisabeth, covering:

    She took the reigns of the family pharmaceutical firm from her fatherThe struggle of turning around the business through rationalization and divestment and critical lessons learned from a tricky timeRe-building into a multi-national, $140m+ API and FDF CDMO with flexibility at its coreInsights into future trends will impact our space, including the aging population, reliance on Asia, and the need for patient affordability to access medicines

    With over twenty years in the industry and an experienced business leader with a track record in growing and transforming businesses, Elisabeth serves on the Board of Medichem SA. She has been the former CEO of Medichem SA., transforming a pure API company into a competitive vertical integrated player.

    A pharmacy graduate by trade, she also serves on the Board of Trustees at the IQS in Barcelona and is President Medicines for Europe. Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry globally.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kendalle Burlin O’Connell, CEO and President of MassBio.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kendalle, covering:

    The story behind how Massachusetts became one of the biggest biotech clusters in the world and why this ecosystem has such an energyKendalle’s non-linear journey into MassBio and how she made an impact (and ruffled some feathers)How she navigated her way to the top of MassBio, including lessons learned along the way and dealing with her inner voiceHer optimistic sentiment for 2024 and the broader impact on global life sciences

    Kendalle leads the organization's strategic direction and drives policy advocacy for the industry to ensure that Massachusetts life sciences companies have the best environment possible to research, develop, manufacture, and commercialize breakthrough therapies and cures for people worldwide. Pursuing innovation and delivering for members are the hallmarks of Kendalle’s more than 15 years at MassBio, including the launch of several multi-year initiatives focused on realizing a diverse and equitable life sciences industry, supporting the continued growth and sustainability of the sector throughout Massachusetts, and providing resources and solutions to companies across the industry value chain.

    A lawyer by trade, she has earned a spot on the Boston Business Journal’s 2023 Power 50: Movement Makers list is ranked number 33 on Boston Magazine’s 2023 list of The 150 Most Influential Bostonians, a 2022 recipient of the Cambridge Chamber of Commerce Inspire Award recognizing outstanding women leaders in the Cambridge community, a 2022 Boston power player as named by Axios, a 2021 executive fellow in the inaugural class of the Civic Action Project Collaborative, and a 2019 Boston Business Journal 40 under 40 honoree which acknowledges a leader’s impact on Massachusetts’ industries.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

  • Founder of the Center for Breakthrough Medicines - now part of SK Pharmteco.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Audrey, covering:

    How a career in real estate financial services led her to the world of cell & gene therapy The story of the creation of the Center for Breakthrough Medicines to its eventual sale and ‘fit’ with SK Pharmteco Why Philadelphia’s 'Cellicon Valley' is becoming one of the hottest life science clusters in the US Timeless tips on fundraising, networking and having a go for young people Her view on the market outlook for 2024 and beyond

    Audrey is a serial entrepreneur, having founded three startups that have exceeded valuations above $1 billion. As Founder of the Center for Breakthrough Medicines, Audrey successfully launched the company, attracted 400 employees from around the globe, raised over $500 million in capital, closed a 15-year $100 million joint venture with the University of Pennsylvania’s Gene Therapy Program, and sold the company to SK Pharmteco.

    Before launching CBM, Audrey founded Discovery Labs, which grew into the largest privately held life science real estate portfolio in the United States. She spent two decades as an executive in private equity, increasing assets under management to over $100 billion.

    Awards have included being selected as the Top Trailblazer in Biotech, Most Influential Philadelphian, Titan 100 (2x), Healthcare Innovation Leader, and Woman of Influence. She is a renowned keynote speaker specializing in Cell and Gene Therapy, DEI initiatives, 'Cellicon Valley', and building bio innovation hubs.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Denise Bowser, Co-Founder and Commercial Director of Onyx Scientific.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Denise, covering:

    The founding story of Onyx and helping the company gain traction in the early yearsA lesson in M&A - being acquired as a great business and being allowed to thrive as a great businessThe non-secret, simple secret sauce of retaining and growing clients over 20 yearsFunctioning as a founder while feeling the force of Menopause... and timely advice for others in the workplaceAdvice for dealing with the downturn - diversification, doubling down on your core competence and customer care

    Having founded Onyx Scientific in 2000, Denise has grown the business into a multi-million dollar CDMO with over 100 employees supporting clients in delivering their clinical programs in the pharmaceutical sector. With over 25 years of experience working with clients globally, Denise has built a successful business built on relationships & trust.

    Denise plays golf in her spare time with a handicap of 16 & is an active member of her club, playing competitively for the team & loves getting out to nature, more recently discovering cold dipping & going on road trips in her campervan.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dominic (Nick) Marasco, Executive President and Chief Commercial Officer at Envision Pharma Group.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Nick, covering:

    Building businesses, learning lots, and selling BioAgilytixWith many options on the table... what was it that attracted him to Envision Pharma GroupThe real-life benefits and tangible impact of AI for pharma and biopharma companiesWhy great science and outstanding services that help will continuously be funded, irrespective of the ebbs and flows of the market

    Dominic (Nick) Marasco is an entrepreneurial executive. He has over 25 years of executive experience in C-suite strategic planning, commercial operations, global business development, clinical Phase III trial design strategy, alliance management, financial resourcing, and P&L oversight within the Pharmaceutical, Biotech, and Medical Device industries.

    Before joining Envision Pharma Group as Executive President and Chief Commercial Officer, Dominic served as Chief Commercial Officer of BioAgilytix, and in his tenure, he was actively involved in two buyer-side acquisitions and three integrations, as well as a seller-side sale of the company to new private equity owners, all within a 24-month timeframe. Before BioAgilytix, he served as Executive Vice President of Global Business Development and Commercial at Syneos Health, where he led the overall strategic direction of the worldwide business development team for the commercial division both in the U.S. and internationally.

    He was previously Head of U.S. Sales for the Neuroscience Business Unit at Amgen, Inc., and before that, Global Commercial Head of Amgen Biosimilars. Dominic has also held commercial positions at Sandoz Biopharmaceuticals (a Novartis company).

    He received his Bachelor of Science in Pharmacy from the Philadelphia College of Pharmacy and Science and ais an alum of the Harvard Business School Advanced Management Program. Dominic resides in Nevada.

    Connect on LinkedIn: here

    ----

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Himanshu Gadgil, CEO at Enzene Biosciences.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Himanshu, covering:

    How a personal tragedy led him from the US to India on a mission to make an impactShifting from a technical to commercial focus to launch several biosimilars in India and beyondBeing at the inception of a big pharma biotech spin-out focused on building a platform of innovation that contributes to societyTaking its cost-effective, continuous manufacturing platform from India to the US via a CDMO vertical focused on novel biologics

    Dr. Himanshu Gadgil serves as the CEO at Enzene Biosciences Ltd. Under his services, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service-based biopharmaceutical company. Prior to Enzene, he worked as the Sr. Vice President at Intas Pharmaceutical Ltd. where he was instrumental in turning around the commercial product pipeline by launching several biosimilar products in multiple geographies.

    During his stint in the US, he led different facets of process and product development at Amgen, spearheading IND, BLA, and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation, where he pioneered the development of QBD, enabling multi-attribute methodologies for biopharmaceutical characterization. Himanshu holds a Ph.D. in Biochemistry from the University of Tennessee and is a passionate scientific leader and innovator with over 50 publications and patents.

    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this special end-of-year episode, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the 50+ episodes and special guest interviews throughout 2023.

    In the second part of our series on the top trends 2023, we dive deep into the dynamic and ever-evolving life sciences sector. From its various life cycles to the winds of change shaping the industry in 2024, there is a positive upturn on the horizon.

    In part two of the top trends from 2023, Raman identified trends including:

    How the M&A market has suffered in a fractured CDMO space over the last 12 monthsThe new breed of biotechs coming to the life sciences market and what they are doing differently to be slimmer and more capital-efficientThe rise of artificial intelligence and the importance it will play in the digitization of the sector Why adaptability and flexibility are causing a sizable impact on an uncertain financial market in the life sciences sectorWhy the term “Green Shoots” is back in the life sciences vocabulary

    Catch up on Part One!

    Subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason Field, President & CEO of Lifesciences Ontario.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jason, covering:

    How the combination of his scientific background and his passion for public policy made him a perfect fit for Lifesciences Ontario (LSO) How the pandemic acted as a wake-up call and catalyst to kickstarting a coordinated industrial investment strategy across Canada The unique ecosystem of Ontario and Toronto, with its blend of plentiful STEM graduates and a thriving start-up and innovation community Why Ontario has gone from ‘flying under the radar’ to becoming a powerhouse cluster in the North American biomanufacturing and advanced therapies space

    Dr. Jason Field is the President and CEO of Life Sciences Ontario (LSO). LSO collaborates with governments, academia, industry and other life science organizations across Canada to promote and encourage commercial success throughout the diverse sector.

    Jason obtained his PhD in Chemistry from the University of Massachusetts and his B.Sc from the University of Waterloo. Jason’s professional experience includes the pharmaceutical industry and the Ontario government before joining LSO as Executive Director in October 2011.

    He was appointed president and CEO in April 2014. He serves on several boards and advisory committees, including UofT’s Translational Research Program, ReMAP, BioTalent Canada, and Research Canada, and co-chairs the Resilient Healthcare Coalition. Jason is the 2017 recipient of the Distinguished Alumni Award from the University of Waterloo and Chair of Ontario’s Life Sciences Council.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Diana Kraskouskaya, co-founder and CEO of Dalriada

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Diana, covering:

    Exactly what ‘the Toronto paradox’ is...How two, seed-funded failures, led to identifying a gap in the market along with access to a rich talent poolThe challenges and realities of starting, growing and scaling a CRO business to over 100 peopleAdvice for other females looking to forge an entrepreneurial career in the drug development space

    Diana brings years of leadership and hands-on cross-disciplinary biotech and drug discovery experience spanning areas of company building, scientific & IP program strategy, and operations.

    She completed an Honors BSc Degree in Molecular Biology and PhD in Medicinal Chemistry from the University of Toronto and is a co-founder of two other biotechs, which have raised > $10 M in VC funding. Diana is the recipient of several entrepreneurship awards, including the RBC Prize for Innovation & Entrepreneurship and the 2018 MNP Future Leaders Awards.

    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this special end-of-year episode, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the 50+ episodes and special guest interviews throughout 2023.

    This special episode covers five key trends Raman identified including:

    The biotech slowdown in 2023 and how it affected the biotech sponsor space Covid rebalancing and the macro-factors that have affected the sector A continued focus on the life sciences supply chain - bringing supply chains closer to homeA continued explosion of novel modalities, including Cell and Gene therapies, mRNA, and so on
 The importance of partnerships within the life sciences life cycle going forward


    The life sciences industry has experienced a year of turbulence, as is often the case in this rapidly evolving sector. However, amidst the challenges, there have been positive changes taking place, and we are optimistic about the prospects for a positive 2024.

    The dynamic nature of the life sciences industry ensures that things are constantly changing. Discoveries, advancements in technology, and evolving market trends shape the landscape and drive innovation. Despite the uncertainties and obstacles faced, the industry continues to adapt and thrive.

    Part two of the series is coming to your favorite streaming platform very soon, so stay tuned for updates on where to find it and in the meantime, enjoy part one.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeffrey P. Kiplinger, Partner at Selling Science.

    Your host, Raman Sehgal, sits down with Jeff to discuss his new book, 'Expert to Entrepreneur'.

    Jeff Kiplinger is a PhD chemist who, after leaving a scientific leadership role at Pfizer in 1998, transitioned to business leadership and an entrepreneurial track. In 2007 he founded Averica Discovery, an analytical drug development CDMO in the Boston area. With solid growth in a tough economy, Averica was an attractive target and was acquired by a Canadian lab services company.

    Jeff left in 2018 and wrote about the experience of changing focus from science to business in his new book, “Expert to Entrepreneur: How to Turn Your Hard-Won Expertise into a Thriving Business”, which made the Amazon Bestseller list in its first week.

    Jeff is passionate about helping scientist entrepreneurs build their businesses. He’s a keynote speaker and coach, leads mastermind groups for scientific founders, and is a co-creator and partner in Selling Science, a consulting firm that helps companies grow their revenue by developing successful sales programs. He still lives in the New England area with his wife Katy, and spends most of his free time outdoors hiking and cycling.

    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Clement Fourny, SVP of Commercial at SmartLabs.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Clement, covering:

    His journey of exploring options and opportunities, which led him to the life sciences space at just the right timeWhy modular labs and manufacturing suites as a service could provide a de-risked and cost-effective solution to those looking to conserve cashHow the SmartLabs turnkey offering enables scientists to focus on the science and not infrastructureThe value of building a collaborative ecosystem and community to harness more innovation

    Clement has a 12-year diverse experience in the Healthcare / Life Sciences industry. Before joining SmartLabs, Clement spent his career at GE and Danaher where he built a track record of strong achievements and execution in sales, commercial operations and operational finance, mobilizing high-performing cross-functional teams to deliver sustainable growth and drive company goals.

    In his prior role at Cytiva (previously known as GE Life Sciences), Clement was responsible for strategically supporting the global commercial organization of 3,000 associates with best-in-class sales operations services.

    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

    Manuel Leal, Corporate Marketing Director at Ardena.

    Eden Turner, Senior Conference Producer at Informa Connect Life Sciences

    Catherine Hunter, Senior Commercial Manager at ramarketing

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology outsourcing events space, covering:

    How industry events are experiencing record numbers in a post-pandemic worldThe role of technology in making the most of trade eventsCalculating the real ROI when it comes to the biggest bucket in your annual marketing/BD budgetThoughts around sustainability and climate impact when it comes to a global event schedule

    Manuel Leal is the Corporate Marketing Director at Ardena, a fully integrated Contract Development and Manufacturing Organization (CDMO) dedicated to advancing new molecules through clinical development. With over two decades of cross-industry experience, he has a unique blend of expertise in pharmaceutical business development and marketing. Manuel has more than 10 years of experience as a Business Development Director within the pharmaceutical CDMO industry. His contributions were instrumental in the growth of Idifarma, an organization that later became part of Ardena.

    Eden Turner received her BSc. In Biological Sciences from Imperial College London. She went on to join Informa as a Conference Producer for two years and now has moved to Senior Conference Producer for three years working on Informa Connect’s Life Science Bioprocessing Portfolio, which expands events across the globe. Main areas of interest include Cell Line Development; Engineering, Upstream; Cell Culture, Manufacturing Strategy; and Bioprocessing 4.0. She is responsible for content creation and assists in market outreach.

    Catherine Hunter is a Senior Commercial Manager at ramarketing and has over a decade of experience in the CRO and CDMO space across large and small molecule. With capabilities in a broad range of commercial disciplines, Catherine supports business development, project management, and events coordination for ramarketing. Passionate about helping companies to achieve their full potential, Catherine uses her business acumen to help ambitious companies fuel growth.

    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kevin Bittorf, Founder and Principal Consultant of SCxCMC.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kevin, covering:

    Joining a little company called Vertex Pharma when it was looking to be innovativeThe leap of faith required to become a consultant, and why helping smaller businesses makes a bigger differenceAn insight into the sentiment of virtual, small, and emerging biotechs after a brutal 12 monthsWhat the most significant factor is in CDMO selection for biotechs, as well as other critical componentsWhy CMC is a crucial investment from pre-IND to phase 2 to get things done on time

    Kevin is an experienced consultant who has demonstrated success in pharmaceutical development (innovator and generics) and technical innovation. Leveraging his extensive experience in GMP, business development, contract manufacturing, and long-term strategy, Kevin partners with biopharma CEOs and executives to guide their companies through groundbreaking pharmaceutical advancements by evaluating strategy, attaining government approvals, and developing new and emerging technologies that improve the development lifecycle.

    He has formed multiple non-profit conferences, including the Advancing Drug Development Forum, which examines how innovations are brought from inception to regulatory approval. He has spent time at Vertex and Trek Therapeutics and advising several CDMOs.

    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr. Andi White, Head of Business Operations & Strategy for the Healthcare Industry Solutions Accelerator at Microsoft.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andi, covering:

    How five years at GE helped develop and shape Andi into a leaderWhy having a broad mindset early on in your career will help you flourish down the lineThe role of tech in revolutionizing clinical trials and drug development spaceHow you should be thinking about and experimenting with AI in terms of data, convenience, and research

    A clinically-savvy Ph.D. with two decades of diverse healthcare experience, Andi White has demonstrated success across all aspects of commercialization, in both start-up and Fortune 100 companies.

    Andi’s corporate experience is bolstered by her years in the San Francisco start-up community, where she participated in the commercialization of several life science companies.

    With a Master’s/Doctorate in Biochemistry from the University of New Hampshire and Postdoctoral research experience at UC Berkeley, Andi has a true passion for the science behind healthcare and the promise of connected data in driving the future of better patient outcomes.

    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

    ** Disclaimer **

    The opinions, beliefs, and viewpoints expressed by Dr. Andrea White on this episode of the Molecule to Market podcast are solely her own and do not reflect the opinions, beliefs, and official policies of Microsoft Corporation.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Charles Ruban, CEO at Verdot.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Charles, covering:

    Crossing the border from supply chain to R&D, lessons learned from a technician turned business leaderCreating the most extensive peanut allergy clinical trial in the world and opting for an IPO instead of a big pharma licensing dealHow a call from a PE firm led to a spectacular exitDesigning and creating downstream bioprocessing equipment in a Patagonia-inspired way - intelligent, sustainable, and functional - is critical for the futureWhy you need to know several biopharma trends, including AI, China R&D, and the fastest-growing therapeutic segment... you need to know

    Over the last 25 years, Charles has held rich and diverse executive leadership positions in fast-growing international healthcare companies. His experience includes Manufacturing, Research and development, Business development, and Global Management in biotechnology and biopharmaceutical companies.

    Charles is the CEO of VERDOT, a key player in bioprocessing, serving advanced solutions to the biotechnology and biopharmaceutical industry worldwide. Before this, he was the co-CEO at HTL Biotechnology, COO of DBV Technologies, and also spent considerable time at Eurogroup Consulting and Stallergenes.

    He has been instrumental in streamlining supply chain operations, establishing strategic alliances, developing and launching therapeutic biologics in Europe, the United States, and Japan, and performing business activities. He has been heavily exposed to investors in both public and private environments.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

  • In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dirk Lange, Head of Life Science Services at MilliporeSigma.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dirk, covering:

    What he has learned from 25 years of bouncing around geographically in terms of cultural differences in understanding clients and colleaguesLife on both sides of the fence as a drug sponsor and a CDMO, including key dynamics a buyer has to considerHow MilliporeSigma has focused on ‘nesting’ its testing services, leading to the use of ’CTDMO'Insights into future trends including the need to deal with novel modalities in an agile way and digitally transform where possible

    Dirk Lange is the Head of Life Science Services at the Life Science business of Merck KGaA, Darmstadt, Germany where he oversees the fully integrated Contract Testing, Development, and Manufacturing Organization (CTDMO) and Contract Testing services for the Life Science business.

    He has over two decades of experience in life science client services organizations and an extensive background in clinical and commercial operations. He has held leadership roles at companies such as KBI Biopharma, Selexis SA, Novartis Biologics, Sandoz Oncology Injectables, and Rentschler Biopharma.

    Lange received his Master Professional (CCI) of Technical Management and his Bachelor Professional (CCI) of Pharmaceutical Technology. He also taught Economics and Operations Management at the Chamber of Commerce and Industry in Ulm, Germany.

    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.